SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?


To: Bill Wexler who wrote (1014)5/12/1999 7:07:00 AM
From: Ploni  Read Replies (1) | Respond to of 10293
 
They're even losing money on an EBITDA basis, though they've cut that to a loss of $440,276 for the 1st quarter 1999, down from an EBITDA loss in the 1st quarter of 1998 of $1,069,986. Their revenues for the 1st quarter 1999 was $11,367,000, up 134% from $4,847,916.

The danger for a potential shorter is that for the 2nd quarter they may get the EBITDA positive, and while EBITDA is BEFORE taxes, depreciation, and amortization, and thus hardly real earnings, it seems to excite some stupid people at brokerage houses. Combine the potential of positive EBITDA earnings with big percentage gains in sales, and the company might move up sharply on broker-hype.



To: Bill Wexler who wrote (1014)2/11/2003 12:53:44 PM
From: Bill Wexler  Respond to of 10293
 
COVERED final slug of Proxymed (PILL) at around $7.50 (reverse split adjusted!).

Just a quick illustration of the value of reverse-splits to short sellers. I have been short PILL since 1999 withoput a single buy-in or squeeze. The shares I am covering today were shorted at a reverse-split-adjusted $200.

Message 9481771

finance.yahoo.com